VAXX (Vaxxinity) NASDAQ $0.0001 pre-market 27 Mar 2026: Top loser, clinical risk

VAXX stock plunged to $0.0001 pre-market on 27 Mar 2026, down -99.60% from the prior close. Vaxxinity, Inc. (VAXX) on the NASDAQ is trading at a microprice after heavy intraday selling and thin volume of 1,264 shares. The move follows clinical and liquidity concerns that connect directly to valuation and short-term trading risk. We review the drivers, key ratios, and near-term price scenarios for U.S.-listed VAXX stock.

What drove the VAXX stock collapse

VAXX stock fell after a steep sell-off that erased most market value. The shares opened at $0.015 then slid to $0.0001 as traders reacted to clinical trial timing and appetite in biotech. Volume was light at 1,264 versus an average of 8,939, which magnified price moves. News flow on the UB-311 and UB-612 programs and recent earnings timing likely amplified selling pressure.

VAXX stock financials and valuation

Vaxxinity reports an EPS of -0.45 and no meaningful revenue per share. The company shows a current ratio of 1.89 and a debt to equity ratio of 1.13, indicating leverage versus book value per share of 0.11. Market cap now reads about $12,678.00 on the NASDAQ in the United States. Price averages are far higher than the current quote: 50-day at 0.003 and 200-day at 0.008.

Technicals and trading metrics for VAXX stock

Technicals show mixed momentum with RSI 47.44 and ADX 65.35, signifying a strong trend but low liquidity. OBV and MFI readings flag unusual flows with MFI at 94.61. The 1-day change is -99.60% and year high sits at 0.05. These metrics point to extreme volatility for traders in the biotechnology sector and limited near-term liquidity for VAXX stock.

Catalysts, news and risks affecting VAXX stock

Key catalysts are clinical readouts for UB-311 and the phase 3 UB-612 program timeline. Recent listings and coverage appear on financial sites such as Investing – Vaxxinity and broader earnings calendars at Investing earnings calendar. Major risks include trial setbacks, dilution, and continued thin trading in the U.S. biotechnology market.

Meyka AI grade and model forecast for VAXX stock

Meyka AI rates VAXX with a score out of 100: the model gives a 61.32 score, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects $0.01 (monthly target). Versus the current price of $0.0001, that implies an upside of 9,900.00%. Forecasts are model-based projections and not guarantees.

Practical trading strategy and price targets for VAXX stock

For traders we outline scenario targets: conservative $0.005 (implied +4,900.00%), base $0.01 (implied +9,900.00%), and optimistic $0.02 (implied +19,900.00%). These targets assume no immediate dilution and a positive clinical update. Risk managers should expect sudden spikes and consider stop levels or position sizing limits given the stock’s microprice and low float. See the Meyka VAXX page for real-time alerts: Meyka VAXX page.

Final Thoughts

VAXX stock sits as a pre-market top loser on 27 Mar 2026, trading at $0.0001 on the NASDAQ in the United States. The drop reflects acute liquidity stress and biotech-specific risk tied to clinical programs and investor appetite. Financially, Vaxxinity shows EPS -0.45, current ratio 1.89, and debt to equity 1.13, which frame capital and solvency pressures. Meyka AI’s model projects a monthly level of $0.01, implying +9,900.00% from the current quote; conservative and optimistic price targets are $0.005 and $0.02 respectively. These model outputs are not guarantees and assume no immediate dilution or negative trial outcomes. Short-term traders face extreme volatility and thin volume, while longer-term investors should watch trial readouts and cash runway before adding exposure. Use tight risk controls and confirm catalyst timelines before acting on VAXX stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.